4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(0.79) per share. This is a 3.66 percent increase over losses of $(0.82) per share from the same period last year.
Mirati Late Saturday, Announced Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response And Long-Term Overall Survival At 2023 World Conference on Lung Cancer
Mirati Therapeutics, Inc. (NASDAQ:MRTX), a commercial stage research and development, biotechnology company, today presented two-year follow-up data from a pooled analysis of the Phase 1/1b Cohort and
